Regeneron Pharmaceuticals, Inc. (REGN) Rating Reiterated by Morgan Stanley

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock had its “equal weight” rating restated by investment analysts at Morgan Stanley in a note issued to investors on Friday. They presently have a $490.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $450.00. Morgan Stanley’s price target points to a potential upside of 4.22% from the stock’s current price.

REGN has been the subject of a number of other research reports. Robert W. Baird cut Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price target for the company. in a report on Tuesday, August 1st. Jefferies Group LLC reiterated a “hold” rating and set a $500.00 price target (up previously from $471.00) on shares of Regeneron Pharmaceuticals in a report on Friday. Zacks Investment Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 4th. Credit Suisse Group cut Regeneron Pharmaceuticals to a “hold” rating and set a $485.00 price target for the company. in a report on Friday, July 14th. Finally, Canaccord Genuity set a $522.00 price target on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, July 28th. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $489.92.

Regeneron Pharmaceuticals (NASDAQ REGN) opened at 469.95 on Friday. The firm has a market cap of $49.83 billion, a PE ratio of 47.15 and a beta of 1.62. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $543.55. The company’s 50 day moving average price is $460.32 and its 200 day moving average price is $451.90.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The business had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter last year, the company posted $2.82 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% on a year-over-year basis. Analysts predict that Regeneron Pharmaceuticals will post $14.92 earnings per share for the current fiscal year.

WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Rating Reiterated by Morgan Stanley” was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://transcriptdaily.com/2017/10/08/regeneron-pharmaceuticals-inc-regn-rating-reiterated-by-morgan-stanley.html.

In related news, SVP Robert E. Landry sold 427 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $493.43, for a total value of $210,694.61. Following the sale, the senior vice president now owns 9,099 shares of the company’s stock, valued at $4,489,719.57. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Robert E. Landry sold 189 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the sale, the chief financial officer now directly owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. In the last three months, insiders sold 89,468 shares of company stock worth $42,312,448. 10.80% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Alpha Windward LLC boosted its position in Regeneron Pharmaceuticals by 0.3% during the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 1 shares during the last quarter. Cleararc Capital Inc. boosted its position in Regeneron Pharmaceuticals by 0.3% during the first quarter. Cleararc Capital Inc. now owns 1,850 shares of the biopharmaceutical company’s stock valued at $717,000 after acquiring an additional 5 shares during the last quarter. Regentatlantic Capital LLC boosted its position in Regeneron Pharmaceuticals by 0.9% during the second quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock valued at $264,000 after acquiring an additional 5 shares during the last quarter. Capital Planning Advisors LLC boosted its position in Regeneron Pharmaceuticals by 2.1% during the second quarter. Capital Planning Advisors LLC now owns 582 shares of the biopharmaceutical company’s stock valued at $286,000 after acquiring an additional 12 shares during the last quarter. Finally, Sequoia Financial Advisors LLC boosted its position in Regeneron Pharmaceuticals by 1.7% during the second quarter. Sequoia Financial Advisors LLC now owns 712 shares of the biopharmaceutical company’s stock valued at $350,000 after acquiring an additional 12 shares during the last quarter. 67.95% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply